Carlos R Oliveira1, Eugene D Shapiro. 1. aDepartment of Pediatrics bDepartment of Epidemiology of Microbial Diseases cDepartment of Investigative Medicine, Yale University Schools of Medicine and of Public Health, Graduate School of Arts and Sciences, New Haven, Connecticut, USA.
Abstract
PURPOSE OF REVIEW: Lyme disease, caused by Borrelia burgdorferi, is the most common vector-borne illness in the United States. The pathogenesis, ecology, and epidemiology of Lyme disease have been well described, and antimicrobial treatment is very effective. There has been controversy about whether infection can persist and cause chronic symptoms despite treatment with antimicrobials. This review summarizes recent studies that have addressed this issue. RECENT FINDINGS: The pathogenesis of persistent nonspecific symptoms in patients who were treated for Lyme disease is poorly understood, and the validity of results of attempts to demonstrate persistent infection with B. burgdorferi has not been established. One study attempted to use xenodiagnosis to detect B. burgdorferi in patients who have been treated for Lyme disease. Another study assessed whether repeated episodes of erythema migrans were due to the same or different strains of B. burgdorferi. A possible cause of persistent arthritis in some treated patients is slow clearance of nonviable organisms that may lead to prolonged inflammation. The results of all of these studies continue to provide evidence that viable B. burgdorferi do not persist in patients who receive conventional antimicrobial treatment for Lyme disease. SUMMARY: Patients with persistent symptoms possibly associated with Lyme disease often provide a challenge for clinicians. Recent studies have provided additional evidence that viable B. burgdorferi do not persist after conventional treatment with antimicrobials, indicating that ongoing symptoms in patients who received conventional treatment for Lyme disease should not be attributed to persistent active infection.
PURPOSE OF REVIEW: Lyme disease, caused by Borrelia burgdorferi, is the most common vector-borne illness in the United States. The pathogenesis, ecology, and epidemiology of Lyme disease have been well described, and antimicrobial treatment is very effective. There has been controversy about whether infection can persist and cause chronic symptoms despite treatment with antimicrobials. This review summarizes recent studies that have addressed this issue. RECENT FINDINGS: The pathogenesis of persistent nonspecific symptoms in patients who were treated for Lyme disease is poorly understood, and the validity of results of attempts to demonstrate persistent infection with B. burgdorferi has not been established. One study attempted to use xenodiagnosis to detect B. burgdorferi in patients who have been treated for Lyme disease. Another study assessed whether repeated episodes of erythema migrans were due to the same or different strains of B. burgdorferi. A possible cause of persistent arthritis in some treated patients is slow clearance of nonviable organisms that may lead to prolonged inflammation. The results of all of these studies continue to provide evidence that viable B. burgdorferi do not persist in patients who receive conventional antimicrobial treatment for Lyme disease. SUMMARY:Patients with persistent symptoms possibly associated with Lyme disease often provide a challenge for clinicians. Recent studies have provided additional evidence that viable B. burgdorferi do not persist after conventional treatment with antimicrobials, indicating that ongoing symptoms in patients who received conventional treatment for Lyme disease should not be attributed to persistent active infection.
Authors: Henry M Feder; Barbara J B Johnson; Susan O'Connell; Eugene D Shapiro; Allen C Steere; Gary P Wormser; W A Agger; H Artsob; P Auwaerter; J S Dumler; J S Bakken; L K Bockenstedt; J Green; R J Dattwyler; J Munoz; R B Nadelman; I Schwartz; T Draper; E McSweegan; J J Halperin; M S Klempner; P J Krause; P Mead; M Morshed; R Porwancher; J D Radolf; R P Smith; S Sood; A Weinstein; S J Wong; L Zemel Journal: N Engl J Med Date: 2007-10-04 Impact factor: 91.245
Authors: Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman Journal: Clin Infect Dis Date: 2006-10-02 Impact factor: 9.079
Authors: I Schwartz; G P Wormser; J J Schwartz; D Cooper; P Weissensee; A Gazumyan; E Zimmermann; N S Goldberg; S Bittker; G L Campbell; C S Pavia Journal: J Clin Microbiol Date: 1992-12 Impact factor: 5.948
Authors: G P Wormser; G Forseter; D Cooper; J Nowakowski; R B Nadelman; H Horowitz; I Schwartz; S L Bowen; G L Campbell; N S Goldberg Journal: JAMA Date: 1992-09-09 Impact factor: 56.272
Authors: Frederik R van de Schoor; Hedwig D Vrijmoeth; Michelle A E Brouwer; Hadewych J M Ter Hofstede; Heidi L M Lemmers; Helga Dijkstra; Collins K Boahen; Marije Oosting; Bart-Jan Kullberg; Joppe W Hovius; Cees C van den Wijngaard; Frank L van de Veerdonk; Mihai G Netea; Leo A B Joosten Journal: Infect Immun Date: 2022-02-07 Impact factor: 3.609
Authors: Sebastian Rauer; Stephan Kastenbauer; Heidelore Hofmann; Volker Fingerle; Hans-Iko Huppertz; Klaus-Peter Hunfeld; Andreas Krause; Bernhard Ruf; Rick Dersch Journal: Ger Med Sci Date: 2020-02-27
Authors: Kenneth Nilsson; Elisabet Skoog; Viktor Jones; Lisa Labbé Sandelin; Christina Björling; Ester Fridenström; Marie Edvinsson; Andreas Mårtensson; Björn Olsen Journal: PLoS One Date: 2021-03-18 Impact factor: 3.240
Authors: Carlos R Oliveira; Christopher Massad; Eugene D Shapiro; Marietta Vazquez Journal: Open Forum Infect Dis Date: 2021-04-17 Impact factor: 3.835